Effect of intravenous β-2 agonist treatment on clinical outcomes in acute respiratory distress syndrome (BALTI-2): a multicentre, randomised controlled trial

Fang Gao Smith, Gavin D Perkins, Simon Gates, Duncan Young, Daniel F McAuley, William Tunnicliffe, Zahid Khan, Sarah E Lamb, BALTI-2 study investigators, S Baudouin, B Cuthbertson, K Rowan, B Williams, F Gao Smith, S Gates, S Lamb, D Young, K Wheatley, J Bion, G Bellingan, F Gao Smith, G Perkins, S Gates, S Lamb, D Young, V Barber, C McCabe, S Duggan, T Melody, C Daffern, E Adey, T Latif, J Bell, R Ezra, B Hoddell, H Johnson, I Ruders, C Snaith, S Dale, H Reay, A McLoughlin, V Gordon, Z Khan, W Tunnicliff, A Krige, J Hull, R Howard-Griffin, C Danbury, R Harding, E Makings, S Afolami, S Shah, S Laha, D McAuley, J Trinder, A Vuylsteke, D Watson, P Jefferson, J Wood, H Black, G Dempsey, F Gao, R Orme, A Arora, S Brett, J Sonksen, R Schoub, S Snape, D Higgins, J Nortje, K Blenk, M Martin, S Graystone, R Daum, R Pugh, I Smith, J Bewley, A Johnston, M Beatty, M Watters, M Grocott, J M Cuesta, D Rogerson, J Park, M Ranganathan, S Tote, T Long, P Alexander, M Khalil, J Little, G Mills, J Hunter, G Mills, M Ghrew, L Milligan, R Ballie, A Padkin, S Wright, S Wright, M Beatty, S Wright, R Schoub, R Sharawi, J Soar, D Highley, D Allen, D Noble, J Ruddy, M Popescu, Fang Gao Smith, Gavin D Perkins, Simon Gates, Duncan Young, Daniel F McAuley, William Tunnicliffe, Zahid Khan, Sarah E Lamb, BALTI-2 study investigators, S Baudouin, B Cuthbertson, K Rowan, B Williams, F Gao Smith, S Gates, S Lamb, D Young, K Wheatley, J Bion, G Bellingan, F Gao Smith, G Perkins, S Gates, S Lamb, D Young, V Barber, C McCabe, S Duggan, T Melody, C Daffern, E Adey, T Latif, J Bell, R Ezra, B Hoddell, H Johnson, I Ruders, C Snaith, S Dale, H Reay, A McLoughlin, V Gordon, Z Khan, W Tunnicliff, A Krige, J Hull, R Howard-Griffin, C Danbury, R Harding, E Makings, S Afolami, S Shah, S Laha, D McAuley, J Trinder, A Vuylsteke, D Watson, P Jefferson, J Wood, H Black, G Dempsey, F Gao, R Orme, A Arora, S Brett, J Sonksen, R Schoub, S Snape, D Higgins, J Nortje, K Blenk, M Martin, S Graystone, R Daum, R Pugh, I Smith, J Bewley, A Johnston, M Beatty, M Watters, M Grocott, J M Cuesta, D Rogerson, J Park, M Ranganathan, S Tote, T Long, P Alexander, M Khalil, J Little, G Mills, J Hunter, G Mills, M Ghrew, L Milligan, R Ballie, A Padkin, S Wright, S Wright, M Beatty, S Wright, R Schoub, R Sharawi, J Soar, D Highley, D Allen, D Noble, J Ruddy, M Popescu

Abstract

Background: In a previous randomised controlled phase 2 trial, intravenous infusion of salbutamol for up to 7 days in patients with acute respiratory distress syndrome (ARDS) reduced extravascular lung water and plateau airway pressure. We assessed the effects of this intervention on mortality in patients with ARDS.

Methods: We did a multicentre, placebo-controlled, parallel-group, randomised trial at 46 UK intensive-care units between December, 2006, and March, 2010. Intubated and mechanically ventilated patients (aged ≥16 years) within 72 h of ARDS onset were randomly assigned to receive either salbutamol (15 μg/kg ideal bodyweight per h) or placebo for up to 7 days. Randomisation was done by a central telephone or web-based randomisation service with minmisation by centre, pressure of arterial oxygen to fractional inspired oxygen concentration (PaO(2)/F(I)O(2)) ratio, and age. All participants, caregivers, and investigators were masked to group allocation. The primary outcome was death within 28 days of randomisation. Analysis was by intention-to-treat. This trial is registered, ISRCTN38366450 and EudraCT number 2006-002647-86.

Findings: We randomly assigned 162 patients to the salbutamol group and 164 to the placebo group. One patient in each group withdrew consent. Recruitment was stopped after the second interim analysis because of safety concerns. Salbutamol increased 28-day mortality (55 [34%] of 161 patients died in the salbutamol group vs 38 (23%) of 163 in the placebo group; risk ratio [RR] 1·47, 95% CI 1·03-2·08).

Interpretation: Treatment with intravenous salbutamol early in the course of ARDS was poorly tolerated. Treatment is unlikely to be beneficial, and could worsen outcomes. Routine use of β-2 agonist treatment in ventilated patients with this disorder cannot be recommended.

Funding: UK Medical Research Council, UK Department of Health, UK Intensive Care Foundation.

Copyright © 2012 Elsevier Ltd. All rights reserved.

Figures

Figure 1
Figure 1
Trial profile
Figure 2
Figure 2
Kaplan-Meier curves for duration of infusions Duration of salbutamol and placebo infusions from 28 days after randomisation. HR=hazard ratio.
Figure 3
Figure 3
Kaplan-Meier curves for mortality Rate of death in the two study groups up to 28 days after randomisation.

References

    1. Brun-Buisson C, Minelli C, Bertolini G. Epidemiology and outcome of acute lung injury in European intensive care units. Results from the ALIVE study. Intensive Care Med. 2004;30:51–61.
    1. Papazian L, Forel JM, Gacouin A. Neuromuscular blockers in early acute respiratory distress syndrome. N Engl J Med. 2010;363:1107–1116.
    1. Rubenfeld GD, Caldwell E, Peabody E. Incidence and outcomes of acute lung injury. N Engl J Med. 2005;353:1685–1693.
    1. Davidson TA, Caldwell ES, Curtis JR, Hudson LD, Steinberg KP. Reduced quality of life in survivors of acute respiratory distress syndrome compared with critically ill control patients. JAMA. 1999;281:354–360.
    1. Heyland DK, Groll D, Caeser M. Survivors of acute respiratory distress syndrome: relationship between pulmonary dysfunction and long-term health-related quality of life. Crit Care Med. 2005;33:1549–1556.
    1. Linden VB, Lidegran MK, Frisen G, Dahlgren P, Frenckner BP, Larsen F. ECMO in ARDS: a long-term follow-up study regarding pulmonary morphology and function and health-related quality of life. Acta Anaesthesiol Scand. 2009;53:489–495.
    1. Maris NA, de Vos AF, Dessing MC. Antiinflammatory effects of salmeterol after inhalation of lipopolysaccharide by healthy volunteers. Am J Respir Crit Care Med. 2005;172:878–884.
    1. Perkins GD, McAuley DF, Richter A, Thickett DR, Gao F. Bench-to-bedside review: beta2-agonists and the acute respiratory distress syndrome. Crit Care. 2004;8:25–32.
    1. Matthay MA, Folkesson HG, Clerici C. Lung epithelial fluid transport and the resolution of pulmonary edema. Physiol Rev. 2002;82:569–600.
    1. Frank JA, Briot R, Lee JW, Ishizaka A, Uchida T, Matthay MA. Physiological and biochemical markers of alveolar epithelial barrier dysfunction in perfused human lungs. Am J Physiol Lung Cell Mol Physiol. 2007;293:L52–L59.
    1. Sakuma T, Okaniwa G, Nakada T, Nishimura T, Fujimura S, Matthay MA. Alveolar fluid clearance in the resected human lung. Am J Respir Crit Care Med. 1994;150:305–310.
    1. Perkins GD, Gao F, Thickett DR. In vivo and in vitro effects of salbutamol on alveolar epithelial repair in acute lung injury. Thorax. 2008;63:215–220.
    1. Perkins GD, McAuley DF, Thickett DR, Gao F. The beta-agonist lung injury trial (BALTI): a randomized placebo-controlled clinical trial. Am J Respir Crit Care Med. 2006;173:281–287.
    1. Bernard GR, Artigas A, Brigham KL. The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med. 1994;149:818–824.
    1. Directive 2001/20/EC of the European Parliament and the Council of the European Union: the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use. Off J Eur Communities. 2001;121:34–44.
    1. Perkins GD, Gates S, Lamb SE, McCabe C, Young D, Gao F. Beta Agonist Lung Injury Trial-2 (BALTI-2) trial protocol: a randomised, double-blind, placebo-controlled of intravenous infusion of salbutamol in the acute respiratory distress syndrome. Trials. 2011;12:113.
    1. The Acute Respiratory Distress Syndrome Network Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network. N Engl J Med. 2000;342:1301–1308.
    1. Wiedemann HP, Wheeler AP, Bernard GR. Comparison of two fluid-management strategies in acute lung injury. N Engl J Med. 2006;354:2564–2575.
    1. Brower RG, Lanken PN, MacIntyre N. Higher versus lower positive end-expiratory pressures in patients with the acute respiratory distress syndrome. N Engl J Med. 2004;351:327–336.
    1. Schoenfeld DA, Bernard GR. Statistical evaluation of ventilator-free days as an efficacy measure in clinical trials of treatments for acute respiratory distress syndrome. Crit Care Med. 2002;30:1772–1777.
    1. Felton TW, Sander R, Al-Aloul M, Dark P, Bentley AM. Can a score derived from the Critical Care Minimum Data Set be used as a marker of organ dysfunction?—a pilot study. BMC Res Notes. 2009;2:77.
    1. Peto R, Pike MC, Armitage P. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. Br J Cancer. 1976;34:585–612.
    1. The Acute Respiratory Distress Syndrome Network. Matthay MA, Brower RG, Carson S. Randomized, placebo-controlled clinical trial of an aerosolized beta-2 agonist for treatment of acute lung injury. Am J Respir Crit Care Med. 2011;342:1301–1308.
    1. Li G, Malinchoc M, Cartin-Ceba R. Eight-year trend of acute respiratory distress syndrome: a population-based study in Olmsted County, Minnesota. Am J Respir Crit Care Med. 2011;183:59–66.
    1. Perkins GD, Nathani N, McAuley DF, Gao F, Thickett DR. In vitro and in vivo effects of salbutamol on neutrophil function in acute lung injury. Thorax. 2007;62:36–42.
    1. Maak CA, Tabas JA, McClintock DE. Should acute treatment with inhaled beta agonists be withheld from patients with dyspnea who may have heart failure? J Emerg Med. 2011;40:135–145.
    1. Au DH, Curtis JR, Every NR, McDonell MB, Fihn SD. Association between inhaled beta-agonists and the risk of unstable angina and myocardial infarction. Chest. 2002;121:846–851.
    1. Briot R, Bayat S, Anglade D, Martiel JL, Grimbert F. Increased cardiac index due to terbutaline treatment aggravates capillary-alveolar macromolecular leakage in oleic acid lung injury in dogs. Crit Care. 2009;13:R166.
    1. Millar EA, Connell JM, Thomson NC. The effect of nebulized albuterol on the activity of the renin-angiotensin system in asthma. Chest. 1997;111:71–74.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit